Group 1 - Tesla's deliveries from April to June totaled 384,122, marking a 13.5% decline compared to the same period last year, indicating a continued slump in production [1] - Wall Street analysts had anticipated approximately 1,000 more deliveries than reported, highlighting a significant shortfall in expectations [1] - Tesla's profits for the first quarter fell by 71% to $409 million from $1.39 billion, with revenues dropping 9% to $19.3 billion, which were also below forecasts [9] Group 2 - Despite the negative delivery figures, analysts at Wedbush expressed optimism about Tesla's future, citing advancements in autonomous driving, robotics, and other technologies as key growth drivers [6] - The stock price of Tesla experienced a 5% decline earlier in the week but rebounded with a 4.5% increase on Wednesday, suggesting some recovery in investor sentiment [6] - The upcoming financial details for Tesla are expected to be published later this month, which may provide further insights into the company's performance [7]

Core Insights - ONWARD Medical N.V. has submitted two significant regulatory applications for its ARC-EX System, including a 510(k) application to the FDA for home use and a CE Mark application for commercialization in the EU [1][7] - The ARC-EX System is the first FDA-cleared technology aimed at improving hand sensation and strength after spinal cord injury (SCI), with strong early demand and positive user feedback indicating a successful market trajectory [2][4] - The company aims to expand access to the ARC-EX System, enhancing its market presence and providing improved convenience for individuals with SCI [4] Regulatory Developments - The 510(k) application seeks to allow marketing of the ARC-EX System for home use in the United States, which would significantly broaden access to the technology [7] - The CE Mark application is intended to enable commercialization of the ARC-EX System in the European Union and other countries that recognize CE Marking [3][7] Clinical Evidence - Positive results from the Pathfinder2 Study indicate that ARC-EX Therapy, combined with activity-based rehabilitation, leads to significant functional improvements in individuals with SCI, including gains in upper body strength, trunk control, and balance over a one-year period [4] Company Background - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement and function in individuals with spinal cord injuries and other movement disabilities, with a history of scientific discovery and clinical studies [5] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the FDA, and is also working on an investigational implantable system called ARC-IM [5] Market Position - The company is headquartered in the Netherlands, with additional facilities in Switzerland and the United States, and is publicly listed on Euronext and OTCQX [6]

Groundbreaking procedures extend ONWARD’s leadership in the rapidly emerging brain-computer interface (BCI) fieldARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilitiesONWARD’s BCI breakthroughs were recently featured on CBS 60 Minutes with Anderson Cooper EINDHOVEN, the Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore move ...